



# Public Formulary Overview – NFLD and Labrador

June 2020

Formulation	Trade Name	Coverage
Long-Acting Stimulants	Adderal XR	Covered – No Restrictions
	Biphentin – 80mg max Concerta – 54 mg max MPH ER / ER-C – 54 mg max Vyvanse – 60 mg max Have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers and/or societal barriers, AND; Have been tried on methylphenidate (immediate release or long-acting formulation) or dexamphetamine (immediate release or long-acting formulation) with unsatisfactory results. Refer to maximum billable dose as listed. Reimbursement will not be considered for Biphentin, Concerta and/or Vyvanse concurrently with methylphenidate (immediate release or long-acting formulation). <i>*Note from CADDRA. Administrative barriers may include things like difficulty or resistance from school personnel in dispensing medication. Societal barriers may include difficulties surrounding stigma, especially within the context of the school environment.</i>	Special Authorization
	Foquest	Not Covered
Short Acting Stimulants	Ritalin Ritalin SR Dexedrine Dexedrine Spansules	Covered – No Restrictions
Non-Stimulant Medications	Strattera	Covered – No restrictions
	Intuniv XR	

Information retrieved from the province of Newfoundland and Labrador in June 2020, [click here](#) to access the most up to date coverage information. [Special Authorization](#) form must be submitted when applicable. for more information on special authorization, [click here](#).